Journal
NATURE BIOTECHNOLOGY
Volume 38, Issue 7, Pages 824-844Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41587-020-0561-9
Keywords
-
Categories
Funding
- Merkin Institute of Transformative Technologies in Healthcare
- US NIH [U01AI142756, RM1HG009490, R01EB022376, R35GM118062]
- HHMI
- Jane Coffin Childs postdoctoral fellowship
- NSF
Ask authors/readers for more resources
A growing arsenal of CRISPR-based tools enables increasingly sophisticated genome editing applications. The development of new CRISPR-Cas genome editing tools continues to drive major advances in the life sciences. Four classes of CRISPR-Cas-derived genome editing agents-nucleases, base editors, transposases/recombinases and prime editors-are currently available for modifying genomes in experimental systems. Some of these agents have also moved rapidly into the clinic. Each tool comes with its own capabilities and limitations, and major efforts have broadened their editing capabilities, expanded their targeting scope and improved editing specificity. We analyze key considerations when choosing genome editing agents and identify opportunities for future improvements and applications in basic research and therapeutics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available